Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer
Following Risperidone, Israeli Firm Feels ‘There Is Real Excitement’ About Olanzapine
Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.
